recombinant human hyaluronidase

DRUG5 trials

Sponsors

Halozyme Therapeutics, Baxalta now part of Shire, Stanford University, Shanghai Henlius Biotech

Conditions

DehydrationHealthyHealthy Adult MaleLymphedemaMalignant NeoplasmPrimary Immunodeficiency Diseases (PID)

Phase 1

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

TerminatedNCT01928030

Stanford UniversityLymphedema, Malignant Neoplasm

Start: 2013-12-31End: 2015-11-30Updated: 2017-03-21

A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects

Not yet recruitingNCT07484893

Shanghai Henlius BiotechHealthy Adult Male

Start: 2026-05-14End: 2026-10-24Target: 24Updated: 2026-03-20

Phase 2

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

CompletedNCT01485796

Baxalta now part of ShirePrimary Immunodeficiency Diseases (PID)

Start: 2011-12-29End: 2013-01-01Updated: 2021-05-19

Phase 4

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

CompletedNCT00656370

Halozyme TherapeuticsHealthy

Start: 2007-12-31End: 2008-01-30Updated: 2018-10-17

Subcutaneous Rehydration Compared to Intravenous Rehydration

CompletedNCT00773175

Halozyme TherapeuticsDehydration

Start: 2008-10-31End: 2009-12-31Updated: 2018-11-07

Related Papers

A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department.

2012-10-1122 citations